Literature DB >> 8722547

Comparative distribution of resistance patterns and serotypes in Pseudomonas aeruginosa isolates from intensive care units and other wards.

F Bert1, N Lambert-Zechovsky.   

Abstract

The resistance patterns and O-serotypes of 2952 Pseudomonas aeruginosa isolates were studied and the relationship between patterns and serotypes was investigated. The penicillinase-producing and cephalosporinase-overproducing phenotypes were significantly more frequent in intensive care units than other wards, but there was no difference for the intrinsic resistance phenotype. The predominant serotypes were O6, O11 and O1. The incidence of serotype O12 was low. O11 isolates were more common in intensive care units and more resistant to all antibiotics than other isolates. Most O12 isolates had a penicillinase-producing phenotype and were resistant to aminoglycosides and ciprofloxacin, but susceptible to fosfomycin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8722547     DOI: 10.1093/jac/37.4.809

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  12 in total

Review 1.  Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.

Authors:  Peter Gilbert; Andrew J McBain
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 2.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

3.  Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate.

Authors:  Julie M Struble; Ryan T Gill
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone.

Authors:  Jean-Paul Pirnay; Daniel De Vos; Christel Cochez; Florence Bilocq; Jean Pirson; Marc Struelens; Luc Duinslaeger; Pierre Cornelis; Martin Zizi; Alain Vanderkelen
Journal:  J Clin Microbiol       Date:  2003-03       Impact factor: 5.948

5.  Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.

Authors:  V Dubois; C Arpin; M Melon; B Melon; C Andre; C Frigo; C Quentin
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

6.  lfnA from Pseudomonas aeruginosa O12 and wbuX from Escherichia coli O145 encode membrane-associated proteins and are required for expression of 2,6-dideoxy-2-acetamidino-L-galactose in lipopolysaccharide O antigen.

Authors:  Jerry D King; Erin F Mulrooney; Evgeny Vinogradov; Bernd Kneidinger; Kristen Mead; Joseph S Lam
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

7.  Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin.

Authors:  M E Falagas; M D Kanellopoulou; D E Karageorgopoulos; G Dimopoulos; P I Rafailidis; N D Skarmoutsou; E A Papafrangas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-23       Impact factor: 3.267

Review 8.  Efflux-mediated drug resistance in bacteria.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Pseudomonas aeruginosa population structure revisited.

Authors:  Jean-Paul Pirnay; Florence Bilocq; Bruno Pot; Pierre Cornelis; Martin Zizi; Johan Van Eldere; Pieter Deschaght; Mario Vaneechoutte; Serge Jennes; Tyrone Pitt; Daniel De Vos
Journal:  PLoS One       Date:  2009-11-13       Impact factor: 3.240

10.  Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes.

Authors:  Qin Lu; Philippe Eggimann; Charles-Edouard Luyt; Michel Wolff; Michael Tamm; Bruno François; Emmanuelle Mercier; Jorge Garbino; Pierre-François Laterre; Holger Koch; Verena Gafner; Michael P Rudolf; Erkan Mus; Antonio Perez; Hedvika Lazar; Jean Chastre; Jean-Jacques Rouby
Journal:  Crit Care       Date:  2014-01-15       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.